Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Completed · Phase 4 · NCT02255656
Conditions: Relapsing Remitting Multiple Sclerosis
At a glance
- Research payments reported, 2025
- $2,500
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 1,062
About the trial
- Sponsor
- Genzyme, a Sanofi Company
- Tested
- alemtuzumab GZ402673 (drug)
- Dates
- Started 2015-01-07; completion 2020-07-15
- Results posted
- Yes
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: * To evaluate long term efficacy of alemtuzumab. * To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. * To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab. * To evaluate as needed re-treatment with alemtuzumab and other DMTs.
From ClinicalTrials.gov, last updated 2022-03-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $2,500 in research payments for this study in 2025 (2 payments).
Products named: Lemtrada
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.